How to Get Farxiga (Dapagliflozin) in West Virginia

Why Dapagliflozin Access Matters in West Virginia

West Virginia carries one of the highest burdens of type 2 diabetes, heart failure, and chronic kidney disease (CKD) in the United States. The CDC estimates that 15.7% of West Virginia adults have diagnosed diabetes, the highest state-level prevalence in the nation [1]. Dapagliflozin addresses all three of these conditions in a single daily tablet.

The drug belongs to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class. It works by blocking glucose reabsorption in the proximal renal tubule, which lowers blood sugar while producing mild osmotic diuresis and natriuresis. These renal and cardiac effects extend its benefits well beyond glycemic control.

In DAPA-HF (N=4,744), dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% compared with placebo (HR 0.74; 95% CI, 0.65 to 0.85; P<0.001) over a median follow-up of 18.2 months [2]. The DAPA-CKD trial (N=4,304) showed a 39% reduction in the composite kidney endpoint (sustained eGFR decline of 50% or greater, end-stage kidney disease, or renal/cardiovascular death) [3]. These outcomes prompted the FDA to expand Farxiga's label to heart failure (2020) and CKD (2021) [4].

For West Virginia patients, the question is rarely whether dapagliflozin is appropriate. It is how to get it.

Telehealth Prescribing of Farxiga in West Virginia

West Virginia law permits licensed prescribers to evaluate patients and write prescriptions via telehealth, including for SGLT2 inhibitors like dapagliflozin. No in-person visit is required before the first prescription, provided the telehealth encounter meets the standard of care.

This matters in a state where 44 of 55 counties are classified as rural [5]. A patient in McDowell County, for example, may live more than an hour from the nearest endocrinologist. Telehealth platforms staffed by physicians, nurse practitioners, or physician assistants licensed in West Virginia can prescribe Farxiga after reviewing labs and medical history remotely.

The prescriber must confirm the clinical indication. For type 2 diabetes, that typically means a documented hemoglobin A1C. For heart failure, it requires an echocardiogram showing reduced ejection fraction (typically <40% for HFrEF, though DAPA-HF enrolled patients with LVEF of 40% or below [2]). For CKD, a confirmed eGFR between 25 and 75 mL/min/1.73 m² with evidence of albuminuria aligns with the DAPA-CKD inclusion criteria [3].

The West Virginia Board of Medicine and the Board of Osteopathic Medicine both recognize synchronous video and audio telehealth as equivalent to in-person evaluation for prescribing decisions [6]. Asynchronous (store-and-forward) encounters alone may not meet the prescribing standard for new controlled or non-controlled medications in every payor's policy.

Who Can Prescribe Farxiga in West Virginia

Four categories of clinicians hold prescriptive authority in West Virginia: physicians (MD and DO), nurse practitioners (NP), and physician assistants (PA). All four can prescribe dapagliflozin.

West Virginia granted full practice authority to nurse practitioners in 2016. An NP with a valid DEA registration and state license can independently evaluate a patient and prescribe Farxiga without physician co-signature [7]. Physician assistants retain a collaborative agreement requirement, but the supervising physician does not need to be physically present at the time of prescribing.

Primary care providers write the majority of SGLT2 inhibitor prescriptions nationally. A 2023 analysis in Diabetes Care found that 61% of new SGLT2 inhibitor prescriptions originated from primary care rather than endocrinology or cardiology [8]. This distribution is especially relevant in West Virginia, where the state has approximately 1.2 endocrinologists per 100,000 residents compared with the national average of 3.4 per 100,000 [9].

If your primary care provider is unfamiliar with dapagliflozin, the 2022 ADA Standards of Care recommend SGLT2 inhibitors as add-on therapy for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or CKD, independent of A1C level or metformin use [10]. Bringing this guideline reference to a visit can shorten the conversation.

Required Labs Before Starting Farxiga

Prescribers in West Virginia will order baseline labs before writing a dapagliflozin prescription. These are standard regardless of whether the visit is in person or via telehealth.

Minimum lab panel:

• Hemoglobin A1C (for diabetes indication): confirms glycemic status. No specific threshold is required for SGLT2 inhibitor initiation per ADA 2022 guidelines, as the drug is recommended for cardiorenal benefit irrespective of A1C [10].
• Serum creatinine and eGFR: the FDA label recommends assessing kidney function before starting. Dapagliflozin's glycemic efficacy diminishes below an eGFR of 45, but its cardiorenal benefits persist down to an eGFR of 25 [4].
• Basic metabolic panel (BMP): screens for baseline potassium and bicarbonate. SGLT2 inhibitors carry a low but real risk of euglycemic diabetic ketoacidosis, making baseline metabolic data clinically useful [11].
• Urinalysis with albumin-to-creatinine ratio (UACR): particularly important for the CKD indication. DAPA-CKD enrolled patients with a UACR of 200 to 5 to 000 mg/g [3].

Some prescribers also request a hemoglobin/hematocrit, as SGLT2 inhibitors can raise hematocrit by 2 to 3 percentage points through hemoconcentration [12]. Telehealth providers typically direct patients to a local Quest Diagnostics, LabCorp, or hospital outpatient lab. West Virginia has Quest locations in Charleston, Huntington, Morgantown, and Wheeling, with LabCorp draw sites in most county seats.

Labs ordered through telehealth carry the same clinical validity as those ordered in person. Results are usually available within 24 to 48 hours.

West Virginia Medicaid and Farxiga Coverage

West Virginia Medicaid does not currently list Farxiga on its preferred drug list. This is a significant barrier in a state where approximately 29% of the adult population is enrolled in Medicaid or the Children's Health Insurance Program [13].

Patients on West Virginia Medicaid have several alternative pathways:

1. Prior authorization exception: a prescriber can submit a prior authorization request documenting that the patient has tried and failed (or has contraindications to) preferred formulary alternatives. For type 2 diabetes, this often means documented trials of metformin and a sulfonylurea. For heart failure, the PA request should reference the DAPA-HF outcome data and the patient's NYHA class [2].

2. AstraZeneca patient assistance program: uninsured or underinsured patients (including those on Medicaid) may qualify for the Farxiga Savings Program or the AZ&Me patient assistance program, which provides the drug at no cost for eligible individuals earning below 400% of the federal poverty level [14].

3. Alternative SGLT2 inhibitor: empagliflozin (Jardiance) may be on the WV Medicaid preferred list. Both drugs share the SGLT2 mechanism, though they were studied in separate trials (EMPA-REG OUTCOME for empagliflozin vs. DAPA-HF and DAPA-CKD for dapagliflozin).

4. Managed Medicaid plans: West Virginia contracts with managed care organizations (MCOs) including Aetna Better Health, The Health Plan, and UniCare. Formulary coverage varies by MCO, and some may cover Farxiga with prior authorization even when fee-for-service Medicaid does not.

Dr. Brent Wisse, an endocrinologist at the University of Washington, has noted: "SGLT2 inhibitors have become first-line therapy for cardiorenal protection, and formulary barriers should not prevent patients from accessing a drug class with mortality-reducing evidence" [15].

Commercial Insurance and Prior Authorization in West Virginia

Most commercial insurers in West Virginia cover Farxiga but require prior authorization (PA). The PA process typically takes 48 to 72 hours, though peer-to-peer reviews can extend this timeline.

Common PA documentation requirements:

• Patient diagnosis (ICD-10 code: E11 for type 2 diabetes, I50 for heart failure, N18 for CKD)
• Relevant labs (A1C, eGFR, UACR, or ejection fraction)
• Documentation of prior therapy trials (varies by plan; some require metformin trial for the diabetes indication)
• Prescriber's clinical rationale referencing guideline recommendations

The ADA/EASD 2022 consensus report recommends SGLT2 inhibitors for patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD regardless of whether the patient is on metformin [10]. Citing this specific guideline in the PA request strengthens the clinical argument.

AstraZeneca offers a manufacturer copay card that can reduce out-of-pocket costs to as little as $0 per month for commercially insured patients, with a maximum annual benefit (typically $3,400 per calendar year) [14]. The card cannot be used with government insurance programs, including Medicare Part D, Medicaid, or Tricare.

For Medicare Part D enrollees, Farxiga's list price of approximately $570 per month means the drug falls into the coverage gap (formerly called the "donut hole"). The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D drugs, effective since 2025, limits total yearly exposure for Medicare beneficiaries [16].

Pharmacy Options for Farxiga in West Virginia

Farxiga is a branded oral tablet dispensed at retail and mail-order pharmacies across West Virginia. The drug does not require refrigeration or special handling.

Retail pharmacy chains with West Virginia locations include CVS, Walgreens, Rite Aid, and Fruth Pharmacy (a regional chain headquartered in Point Pleasant, WV). Independent pharmacies in rural counties also stock or can order Farxiga within one to two business days through their wholesale distributor.

Mail-order pharmacy is often more cost-effective for maintenance medications. Express Scripts, CVS Caremark, and OptumRx all dispense Farxiga via 90-day mail order, which may reduce copays compared with three separate 30-day retail fills.

West Virginia also licenses 503A compounding pharmacies. These pharmacies can compound medications from bulk ingredients for individual patient prescriptions. Dapagliflozin as a compounded formulation is theoretically possible under 503A rules, though branded Farxiga is widely available and FDA-approved, making compounding unusual for this particular drug.

The 2023 KIDGO clinical practice guideline for CKD management reinforced the recommendation for SGLT2 inhibitors and stated: "We recommend treating patients with type 2 diabetes, CKD, and an eGFR of 20 mL/min/1.73 m² or greater with an SGLT2 inhibitor" [17]. That recommendation extended the eGFR threshold below the original DAPA-CKD enrollment criterion of 25, which may affect prescribing patterns in West Virginia's CKD population.

Transferring a Farxiga Prescription to West Virginia

Patients relocating to West Virginia can transfer an existing Farxiga prescription from another state. West Virginia accepts prescription transfers from all 50 states under the National Association of Boards of Pharmacy (NABP) guidelines.

The process is straightforward. Call the receiving West Virginia pharmacy and provide the name and phone number of the original pharmacy. The pharmacist initiates the transfer directly. For controlled substances, federal transfer rules are stricter, but dapagliflozin is not a controlled substance and faces no transfer restrictions.

If the prescription has no remaining refills, a telehealth visit or in-person appointment with a West Virginia-licensed prescriber is needed to write a new prescription. Lab work from the prior state is generally accepted, provided it is less than 6 to 12 months old (provider discretion applies).

Patients moving from states with different Medicaid programs should verify coverage with their new West Virginia MCO, as formulary status and PA requirements differ across state Medicaid programs.

Timeline: From First Visit to First Dose

The path from initial clinical evaluation to filling a Farxiga prescription in West Virginia typically follows this sequence:

1. Day 1: telehealth or in-person visit; lab orders placed
2. Days 2 to 3: labs drawn and resulted
3. Day 3: prescriber reviews labs, writes prescription, submits PA if required
4. Days 3 to 6: PA decision returned (48 to 72 hours for most commercial plans)
5. Day 6 to 7: prescription filled at pharmacy

Total elapsed time: roughly 5 to 7 business days from first visit to first dose when prior authorization is needed. Without PA requirements (self-pay or plans without PA), patients can fill the prescription within 2 to 3 days of the initial visit.

Delays most commonly occur at the PA stage. If a PA is denied, prescribers can request a peer-to-peer review (a phone call between the prescriber and the insurer's medical director), which adds 3 to 5 business days. Appeal success rates for SGLT2 inhibitors are generally high when the clinical rationale cites guideline-concordant indications [10].